| 1 |
34958553 | Proteomic Analysis Reveals Low-Dose PARP Inhibitor-Induced Differential Protein Expression in BRCA1-Mutated High-Grade Serous Ovarian Cancer Cells. | 2022 Feb 2 |
1 |
| 2 |
35205643 | Precision Medicine for BRCA/PALB2-Mutated Pancreatic Cancer and Emerging Strategies to Improve Therapeutic Responses to PARP Inhibition. | 2022 Feb 11 |
1 |
| 3 |
35210863 | Guidelines for Management of Treatment-Emergent Adverse Events During Rucaparib Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer. | 2022 |
1 |
| 4 |
35298905 | Rucaparib for BRCA1/2-mutated pretreated ovarian cancer: reflections from the ARIEL4 trial. | 2022 Apr |
1 |
| 5 |
35594523 | The growing role of rucaparib in contemporary treatment of metastatic prostate cancer: a review of efficacy and guidance for side effect management. | 2022 May 26 |
1 |
| 6 |
35614267 | Imaging PARP with [18F]rucaparib in pancreatic cancer models. | 2022 May 26 |
1 |
| 7 |
33145877 | FDA Approval Summary: Rucaparib for the Treatment of Patients with Deleterious BRCA-Mutated Metastatic Castrate-Resistant Prostate Cancer. | 2021 Feb |
2 |
| 8 |
33515503 | Rucaparib in patients with BAP1-deficient or BRCA1-deficient mesothelioma (MiST1): an open-label, single-arm, phase 2a clinical trial. | 2021 Jun |
1 |
| 9 |
33753748 | Cisplatin +/- rucaparib after preoperative chemotherapy in patients with triple-negative or BRCA mutated breast cancer. | 2021 Mar 22 |
1 |
| 10 |
33827356 | Olaparib and rucaparib for the treatment of DNA repair-deficient metastatic castration-resistant prostate cancer. | 2021 Aug |
1 |
| 11 |
33941784 | Molecular and clinical determinants of response and resistance to rucaparib for recurrent ovarian cancer treatment in ARIEL2 (Parts 1 and 2). | 2021 May 3 |
1 |
| 12 |
33970687 | Phase II Study of Maintenance Rucaparib in Patients With Platinum-Sensitive Advanced Pancreatic Cancer and a Pathogenic Germline or Somatic Variant in BRCA1, BRCA2, or PALB2. | 2021 Aug 1 |
2 |
| 13 |
34103386 | Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase III trial ARIEL3. | 2021 Jul |
1 |
| 14 |
34459606 | Copper-Mediated Radiosynthesis of [18F]Rucaparib. | 2021 Sep 17 |
1 |
| 15 |
34549539 | Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety. | 2021 Oct |
1 |
| 16 |
34598946 | Response to Rucaparib in BRCA-Mutant Metastatic Castration-Resistant Prostate Cancer Identified by Genomic Testing in the TRITON2 Study. | 2021 Dec 15 |
1 |
| 17 |
34778690 | Differential Activity of PARP Inhibitors in BRCA1- Versus BRCA2-Altered Metastatic Castration-Resistant Prostate Cancer. | 2021 |
1 |
| 18 |
34904808 | PARP Inhibition in Advanced Prostate Cancer. | 2021 Nov-Dec 01 |
1 |
| 19 |
32367009 | PARP inhibitors as a new therapeutic option in metastatic prostate cancer: a systematic review. | 2020 Dec |
1 |
| 20 |
32371137 | 'PARP'ing fibrosis: repurposing poly (ADP ribose) polymerase (PARP) inhibitors. | 2020 Jul |
1 |
| 21 |
32427631 | Poly(ADP-ribose) polymerase inhibitors in prostate and urothelial cancer. | 2020 Jul |
1 |
| 22 |
32717529 | The ups and downs of Poly(ADP-ribose) Polymerase-1 inhibitors in cancer therapy-Current progress and future direction. | 2020 Oct 1 |
1 |
| 23 |
32795228 | Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration. | 2020 Nov 10 |
1 |
| 24 |
32814685 | When and How to Use PARP Inhibitors in Prostate Cancer: A Systematic Review of the Literature with an Update on On-Going Trials. | 2020 Oct |
1 |
| 25 |
32927276 | BET, SRC, and BCL2 family inhibitors are synergistic drug combinations with PARP inhibitors in ovarian cancer. | 2020 Oct |
1 |
| 26 |
32963528 | BRCA Mutations in Prostate Cancer: Prognostic and Predictive Implications. | 2020 |
1 |
| 27 |
29166829 | Rucaparib: A Poly(ADP-Ribose) Polymerase Inhibitor for BRCA-Mutated Relapsed Ovarian Cancer. | 2019 Apr |
2 |
| 28 |
30425037 | BRCA Reversion Mutations in Circulating Tumor DNA Predict Primary and Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma. | 2019 Feb |
3 |
| 29 |
30589644 | PARP inhibition enhances tumor cell-intrinsic immunity in ERCC1-deficient non-small cell lung cancer. | 2019 Mar 1 |
1 |
| 30 |
30830551 | Rucaparib: A Review in Ovarian Cancer. | 2019 Apr |
1 |
| 31 |
30912451 | Advances in the use of PARP inhibitors for BRCA1/2-associated breast cancer: talazoparib. | 2019 May |
1 |
| 32 |
30939057 | Germline BRCA1 Deletion as Driver Mutation for Metastatic Urachal Adenocarcinoma in Patient Who Achieved Complete Response to Rucaparib. | 2019 May |
1 |
| 33 |
30940721 | Maintenance Rucaparib Controls Some Pancreatic Cancers. | 2019 Jun |
1 |
| 34 |
31069647 | Current Systemic Treatment Landscape of Advanced Gynecologic Malignancies. | 2019 Jun |
1 |
| 35 |
31191001 | Current status and future prospects of PARP inhibitor clinical trials in ovarian cancer. | 2019 |
1 |
| 36 |
31404966 | Clinical Development of PARP Inhibitors in Treating Metastatic Castration-Resistant Prostate Cancer. | 2019 Aug 9 |
1 |
| 37 |
31685558 | Antitumor activity of the poly(ADP-ribose) polymerase inhibitor rucaparib as monotherapy in patients with platinum-sensitive, relapsed, BRCA-mutated, high-grade ovarian cancer, and an update on safety. | 2019 Nov |
3 |
| 38 |
29189915 | Targeting BRCA1/2 deficient ovarian cancer with CNDAC-based drug combinations. | 2018 Feb |
1 |
| 39 |
29605737 | Rucaparib: An emerging parp inhibitor for treatment of recurrent ovarian cancer. | 2018 May |
1 |
| 40 |
29606854 | Rucaparib: a novel PARP inhibitor for BRCA advanced ovarian cancer. | 2018 |
1 |
| 41 |
29977351 | Rucaparib in ovarian cancer: an update on safety, efficacy and place in therapy. | 2018 |
1 |
| 42 |
30051098 | Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation. | 2018 |
1 |
| 43 |
30105925 | Rucaparib in ovarian cancer: extending the use of PARP inhibitors in the recurrent disease. | 2018 Dec |
2 |
| 44 |
30266954 | Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian carcinoma. | 2018 Sep 28 |
4 |
| 45 |
30426062 | Pharmacokinetics and clinical response to single agent rucaparib in a dialysis dependent patient with BRCA associated breast and recurrent ovarian cancer. | 2018 Nov |
2 |
| 46 |
30535808 | Using PARP Inhibitors in the Treatment of Patients With Ovarian Cancer. | 2018 Nov 15 |
1 |
| 47 |
28057616 | Rucaparib Approved for Ovarian Cancer. | 2017 Feb |
1 |
| 48 |
28222073 | A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours. | 2017 Mar 28 |
1 |
| 49 |
28250698 | Pharmaceutical Approval Update. | 2017 Mar |
1 |
| 50 |
28264872 | A Phase I-II Study of the Oral PARP Inhibitor Rucaparib in Patients with Germline BRCA1/2-Mutated Ovarian Carcinoma or Other Solid Tumors. | 2017 Aug 1 |
2 |